Compare Abbott Laboratories (ABT) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Capri Holdings Ltd — how do they compare? Abbott Laboratories trades at $110.19 (market cap $187.95B), while Capri Holdings Ltd trades at $15.34 (market cap $1.75B). The key difference: Abbott Laboratories is far larger — about 107.4× Capri Holdings Ltd's market cap, and Abbott Laboratories pays a 2.32% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| ABT | CPRI | |
|---|---|---|
Market Cap | $187.95B | $1.75B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $27.66 |
52-Week Low | $82.57 | $14.98 |
Enterprise Value | $214.96B | $3.03B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CPRI trades at $15.43, down 65% over five years but showing recent earnings momentum with three consecutive quarterly beats. The stock faces bearish technical signals with moving averages indicating downward pressure, while fundamentals reveal declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Analyst consensus sits at $19.60 with mixed ratings (44% Buy, 52% Hold), reflecting cautious optimism about the company's turnaround strategy post-Versace sale.
The investment case hinges on CPRI's ability to stabilize Michael Kors and grow Jimmy Choo profitability, but risks include ongoing revenue declines, luxury market softness, and high debt levels. With the current price near 52-week lows and 27% upside to consensus target, the stock offers potential for recovery if management executes its revamp plans successfully, though macroeconomic headwinds and brand challenges remain significant concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
